Register

Symposium @ Society for Immunotherapy of Cancer (SITC) 2025 Annual Meeting

November 8, 2025  12:30pm - 1:30pm

Lunch Included

LEGION-100 Phase 2 Trial Enrolling: 3rd Generation Immunotherapy for mCRPC Patients

Join us to learn about a novel combination immunotherapy that could change the treatment landscape of mCRPC.

Chesapeake JKL Room

Lunch included, seating is limited

Register

Symposium Overview

Description of program and speakers

Title: LEGION-100 Phase 2 Trial Enrolling – 3rd Generation Immunotherapy for mCRPC Patients

Speakers: Charles J. Link, MD (Adjunct Professor, Lankenau Institute for Medical Research & Executive Chairman, Syncromune), Leonard J. Appleman, MD, PhD (Associate Professor of Medicine, University of Pittsburgh, Division of Hematology/Oncology), and George C. Prendergast, PhD (President & CEO, Lankenau Institute for Medical Research, Main Line Health).

Description: Leading investigators and clinical innovators will provide in-depth insights into SYNC-T SV-102, a novel third-generation combination intratumoral/locoregional immunotherapy designed to elicit a systemic antitumor response in patients with metastatic castration-resistant prostate cancer (mCRPC).

This session will showcase Phase 1 clinical results demonstrating safety, immune activation, and early signs of efficacy, highlighting how SYNC-T SV-102 is reshaping the therapeutic landscape for advanced prostate cancer.

Largely, the symposium will spotlight the LEGION-100 Phase 2 clinical trial, now actively enrolling patients and recruiting clinical trial sites across the U.S. Investigators will share insights into the trial’s design, scientific rationale, and the opportunity for institutions to partner in evaluating this cutting-edge immunotherapy.

Key Topics

Immunotherapy in mCRPC

Trials and data to date.

Novel 3rd Generation Immunotherapy

Combination intratumoral / locoregional

SYNC-T Therapy SV-102

Phase 1 data in mCRPC

LEGION-100 Phase 2 Trial for mCRPC

Trial design, rationale, participation.

Speakers

The symposium will feature three speakers who have broad expertise on the SYNC-T Therapy

Charles J. Link, M.D.

Adjunct Professor, Lankenau Institute for Medical Research & Executive Chairman, Syncromune

Leonard J. Appleman, MD, PhD

Associate Professor of Medicine, University of Pittsburgh, Division of Hematology/Oncology

George C. Prendergast, Ph.D.

President & CEO, Lankenau Institute for Medical Research, Main Line Health

Program Details

12:30pm – 1:30pm

12:30pm - 12:45pm

  • Previous immunotherapy trials for mCRPC and discussion of outcomes

  • Introduction to SYNC-T, a novel third-generation combination intratumoral/locoregional immunotherapy

  • Potential advantages of SYNC-T Therapy in treating mCRPC

12:45pm - 1:05pm

  • Overview of Phase 1 trial of SYNC-T Therapy SV-102 in mCRPC

  • Outcomes: safety, efficacy, pharmacokinetics

  • Conclusions and key takeaways

1:05pm - 1:20pm

  • LEGION-100 Phase 2 Dose Escalation and Dose Optimization Trial design

  • Key inclusion and exclusion criteria

  • How to refer patients or become a clinical trial site

1:20pm - 1:30pm

  • Question and Answer Session

Conference Directions

Chesapeake JKL Room

Society for Immunotherapy of Cancer (SITC) 2025 Annual Meeting
Gaylord National Resort & Conference Center
201 Waterfront St.
Oxon Hill, MD  20745
301-965-4000
Chesapeake JKL Room

;